Chirantan Chatterjee
Chirantan Chatterjee
ICICI Bank Chair & Faculty Member (IIMA), Visiting Fellow, Hoover Institution
Verified email at - Homepage
Cited by
Cited by
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry
L Branstetter, C Chatterjee, MJ Higgins
The RAND Journal of Economics 47 (4), 857-890, 2016
Does environmental regulation indirectly induce upstream innovation? New evidence from India
P Chakraborty, C Chatterjee
Research Policy 46 (5), 939-955, 2017
Strong medicine: Patent reform and the emergence of a research-driven pharmaceutical industry in India
A Arora, L Branstetter, C Chatterjee
NBER Conference on Location of Biopharmaceutical Activity, Boston, MA, 7-8, 2008
Ethical issues in health care sector in India
C Chatterjee, V Srinivasan
IIMB Management Review 25 (1), 49-62, 2013
Starving (or fattening) the golden goose?: generic entry and the incentives for early-stage pharmaceutical innovation
L Branstetter, C Chatterjee, MJ Higgins
National Bureau of Economic Research, 2014
The consumer welfare implications of governmental policies and firm strategy in markets for medicines
C Chatterjee, K Kubo, V Pingali
Journal of Health Economics 44, 255-273, 2015
Strong medicine? Patent reform and the transformation of the Indian pharmaceutical industry
A Arora, L Branstetter, C Chatterjee, K Saggi
mimeo, 2009
Gender and its rising role in modern Indian innovation and entrepreneurship
C Chatterjee, S Ramu
IIMB Management Review 30 (1), 62-72, 2018
Mitigating regulatory impact: the case of partial price controls on metformin in India
A Bhaskarabhatla, C Chatterjee, P Anurag, E Pennings
Health policy and planning 32 (2), 194-204, 2017
Price Control and Access to Drugs: The Case of India’s Malaria Market
D Mohapatra, C Chatterjee
Working Paper. Cornell University, 2015
Hit where it hurts: cartel policing using targeted sales and supply embargoes
A Bhaskarabhatla, C Chatterjee, B Karreman
The Journal of Law and Economics 59 (4), 805-846, 2016
Innovation and internationalisation in the Indian software industry: Wipro–Going forward: Interview with Rishad Premji, Chief Strategy Officer, Wipro Limited
C Chatterjee
IIMB management Review 26 (1), 59-64, 2014
Government health insurance and spatial peer effects: New evidence from India
C Chatterjee, R Joshi, N Sood, P Boregowda
Social Science & Medicine 196, 131-141, 2018
The role of physicians in prescribing irrational fixed-dose combination medicines in India
A Bhaskarabhatla, C Chatterjee
Social science & medicine 174, 179-187, 2017
Fundamental Patent Reform and the Private Returns to R&D The Case of Indian Pharmaceuticals
C Chatterjee
Women’s Disempowerment and Preference for Risky Skin Whitening Products: Experimental Evidence from India
A Adbi, C Chatterjee, Z Kinias, J Singh
INSEAD Working Paper, 2019
First-mover advantages before and after TRIPS: Evidence from the Indian pharmaceutical industry
A Bhaskarabhatla, C Chatterjee
Available at SSRN 2154510, 2012
Moving beyond the valley of death: regulation and venture capital investments in early-stage biopharmaceutical firms
Y Kim, C Chatterjee, MJ Higgins
National Bureau of Economic Research Working Paper Series, 2018
Maximizing local value addition in Indian mobile phone manufacturing: a practical phased approach
T Pathak, C Chatterjee, N Shah
IIM Bangalore Research Paper, 2016
The welfare implications of patent protection, pricing, and licensing in the Indian oral anti-diabetic drug market
C Chatterjee, K Kubo, V Pingali
IIM Bangalore Research Paper, 2013
The system can't perform the operation now. Try again later.
Articles 1–20